Literature DB >> 24136742

Vitamin D receptor rs2228570 polymorphism and susceptibly to ovarian cancer: a meta-analysis.

Su Li1, Hui Xu, Shuang-Cheng Li, Xiang-Qun Qi, Wen-Juan Sun.   

Abstract

The role of vitamin D receptor (VDR) rs2228570 polymorphism on the risk of ovarian cancer has been studied in many studies, but the relationship between VDR rs2228570 polymorphism and ovarian cancer is still unclear. We thus performed a meta-analysis of published studies to provide a comprehensive assessment of the association. Fourteen individual studies with a total of 10,964 subjects were finally included into the meta-analysis. We assessed the association by calculating the pooled odds ratio (OR) with 95 % confidence intervals (95 % CI). There was no heterogeneity among those included studies. Meta-analysis of 14 studies showed that the VDR rs2228570 polymorphism was associated with risk of ovarian cancer under three main comparison models (T versus C: OR = 1.09, 95 % CI 1.03 to 1.15, P = 0.004; TT versus CC: OR = 1.17, 95 % CI 1.04 to 1.32, P = 0.01; and TT/CT versus CC: OR = 1.12, 95 % CI 1.03 to 1.21, P = 0.007). Subgroup analysis in Caucasians further identified the obvious association. There was no evidence of publications bias. These data from the meta-analysis suggest that VDR rs2228570 polymorphism is associated with risk of ovarian cancer in Caucasians. More studies are warranted to assess the association between the VDR rs2228570 polymorphism and ovarian cancer in Asians and Africans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24136742     DOI: 10.1007/s13277-013-1175-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

Review 1.  The hair cycle and Vitamin D receptor.

Authors:  Marie B Demay
Journal:  Arch Biochem Biophys       Date:  2011-10-07       Impact factor: 4.013

2.  Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Michael E Carney; Rachel T Palmieri; Paul D P Pharoah; Honglin Song; Estrid Hogdall; Susanne Kruger Kjaer; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Marc T Goodman
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.

Authors:  Angela J Ziebarth; Charles N Landen; Ronald D Alvarez
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 5.  Vitamin D, disease and therapeutic opportunities.

Authors:  Lori A Plum; Hector F DeLuca
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 6.  Inherited risk of ovarian cancer and the implications for screening.

Authors:  Simon A Gayther
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

Review 7.  Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer.

Authors:  Marjorie L McCullough; Roberd M Bostick; Tinisha L Mayo
Journal:  Annu Rev Nutr       Date:  2009       Impact factor: 11.848

8.  Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.

Authors:  Shelley S Tworoger; Margaret A Gates; Margaret A Gate; I-Min Lee; Julie E Buring; Linda Titus-Ernstoff; Daniel Cramer; Susan E Hankinson
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

9.  Ovarian cancer.

Authors:  Bryan T Hennessy; Robert L Coleman; Maurie Markman
Journal:  Lancet       Date:  2009-09-28       Impact factor: 79.321

10.  Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

View more
  7 in total

1.  Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations.

Authors:  Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Paweł P Jagodzinski
Journal:  Oncol Lett       Date:  2015-12-15       Impact factor: 2.967

2.  Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer.

Authors:  Teresa Granato; Lucia Manganaro; Luca Petri; Maria Grazia Porpora; Valentina Viggiani; Antonio Angeloni; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2015-09-09

3.  What do we know and do not know about vitamin D?: a causal association between vitamin D receptor genetic polymorphism and hypertension.

Authors:  Yalcin Solak; Adrian Covic; Mehmet Kanbay
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-08       Impact factor: 3.738

4.  Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Cezary Jochymski; Andrzej T Slominski
Journal:  Oncol Rep       Date:  2014-12-11       Impact factor: 3.906

5.  Vitamin D receptor rs2228570 polymorphism is associated with LH levels in men exposed to anabolic androgenic steroids.

Authors:  Linda Björkhem-Bergman; Mikael Lehtihet; Anders Rane; Lena Ekström
Journal:  BMC Res Notes       Date:  2018-01-19

6.  Epidemiology of ovarian cancer: a review.

Authors:  Brett M Reid; Jennifer B Permuth; Thomas A Sellers
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

Review 7.  Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms.

Authors:  Andraž Dovnik; Nina Fokter Dovnik
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.